Home > Focus Areas > Breast Cancer Connect > Post
2yr
Cost-Effectiveness Analysis of Abemaciclib With Endocrine Therapy (ET) Versus ET Alone for HR+, HER2−, Node-Positive, High-Risk Early Breast Cancer in Italy
Source : https://journals.aboutscience.eu/index.php/grhta/article/view/2561
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
Abemaciclib plus ET is a cost-effective treatment option vs ET alone for those with HR+, HER2− node-positive EBC at high risk of recurrence in Italy.
-
Albert Dekker2yrif EU feels it is cost effective it may be. I am not sure how different is the price of Verzenio in EU vs US. it very well could be 70% less